WuXi Biologics, part of WuXi AppTec, a Shanghai, China-headquartered contract service provider, has begun construction of an antibody-drug conjugate (ADC) service center in Wuxi, China.

The $20-million 6,000-square-meter facility will be operational in 2019 and provide integrated services from concept to commercialization for biologics conjugates, including ADCs and other protein conjugates.

WuXi Biologics said it plans to build the site into an ADC research and development and manufacturing platform that will meet US, European Union, and Chinese cGMP standards.

The company recently announced plans to invest $60 million to establish a biologics clinical and commercial manufacturing facility in Worcester, Massachusetts. In May 2018, WuXi Biologics also announced plans to invest 80 million Singapore dollars (US $60 million) to establish a biologics manufacturing facility in Singapore as well as plans to build an integrated biologics development, clinical, and commercial manufacturing center in Shijiazhuang, Hebei province, North China.

Source: WuXi Biologics